Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2167-2174

  Reginato, E ^a,b   Mroz, P ^a,c,d   Chung, H ^a,c   Kawakubo, M ^a   Wolf, P ^b   Hamblin, M R ^a,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

anti tumour immunity; CT26 tumour; photodynamic therapy; regulatory T cells; TGF

Indexed keywords

CYCLOPHOSPHAMIDE; TRANSFORMING GROWTH FACTOR BETA; VERTEPORFIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; LONG TERM SURVIVAL; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LYMPH NODES; MICE; MICE, INBRED BALB C; PHOTOCHEMOTHERAPY; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84885947054     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.580     Document Type: Article

References (48)

1. Abe S, Kurata M, Suzuki S, Yamamoto K, Aisaki K, Kanno J, Kitagawa M (2012) Minichromosome maintenance 2 bound with retroviral Gp70 is localized to cytoplasm and enhances DNA-damage-induced apoptosis. PLoS One 7(6): e40129.
2. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, Korbelik M, Moan J, Mroz P, Nowis D, Piette J, Wilson BC, Golab J (2011) Photodynamic therapy of cancer: An update. CA Cancer J Clin 61(4): 250-281.
3. Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65(1): 87-92.
4. Awwad M, North RJ (1989) Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4? suppressor T-cells. Cancer Res 49(7): 1649-1654.
5. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6(7): 535-545.
6. Castano AP, Mroz P, Wu MX, Hamblin MR (2008) Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci USA 105(14): 5495-5500.
7. Cecic I, Korbelik M (2002) Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 183(1): 43-51.
8. Cecic I, Stott B, Korbelik M (2006) Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int Immunopharmacol 6(8): 1259-1266.
9. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP (1996) Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156(1): 224-231.
10. Curiel TJ, Coukos G, Zou L,Alvarez X, Cheng P,MottramP, Evdemon-HoganM, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9): 942-949.
11. Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3(5): 380-387.
12. Dougherty TJ (2002) An update on photodynamic therapy applications. J Clin Laser Med Surg 20(1): 3-7.
13. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. JNCI 90(12): 889-905.
14. Elliott RL, Blobe GC (2005) Role of transforming growth factor Beta in human cancer. J Clin Oncol 23(9): 2078-2093.
15. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(?) T cells to the antitumor immune response. J Exp Med 201(10): 1591-1602.
16. Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2011) DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci 10(5): 670-680.
17. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome. Cancer Immunol Immunother 61(3): 353-362.
18. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4?CD25? regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34(2): 336-344.
19. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25? regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32(11): 3267-3275.
20. Gollnick SO, Owczarczak B, Maier P (2006) Photodynamic therapy and anti-tumor immunity. Lasers Surg Med 38(5): 509-515.
21. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55(1): 145-157.
22. Hodi FS, O?Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8): 711-723.
23. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 93(18): 9730-9735.
24. Huang Z (2005) A review of progress in clinical photodynamic therapy. Tech Canc Res Treat 4(3): 283-293.
25. Jalili A, Makowski M, Switaj T, Nowis D, Wilczynski GM, Wilczek E, Chorazy-Massalska M, Radzikowska A, Maslinski W, Bialy L, Sienko J, Sieron A, Adamek M, Basak G, Mroz P, Krasnodebski IW, Jakobisiak M, PDT plus cyclophosphamide of CT26 mouse tumours BRITISH JOURNAL OF CANCER www.bjcancer.com | DOI:10.1038/bjc.2013.580 2173
26. Golab J (2004) Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 10(13): 4498-4508.
27. Korbelik M (1996) Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 14(5): 329-334.
28. Korbelik M, Cecic I, Merchant S, Sun J (2008) Acute phase response induction by cancer treatment with photodynamic therapy. Int J Cancer 122(6): 1411-1417.
29. Korbelik M, Sun J, Cecic I (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: Relevance for tumor response. Cancer Res 65(3): 1018-1026.
30. Krosl G, Korbelik M, Dougherty GJ (1995) Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer 71(3): 549-555.
31. Letterio JJ, Roberts AB (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161.
32. Loeffler M, Kruger JA, Reisfeld RA (2005) Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 65(12): 5027-5030.
33. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(?)25? T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7): 2862-2868.
34. McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, McDuffie M, Slansky JE (2008) Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 26(15): 1863-1873.
35. Mroz P, Hamblin MR (2011) The immunosuppressive side of PDT. Photochem Photobiol Sci 10(5): 751-758.
36. Mroz P, Szokalska A, Wu MX, Hamblin MR (2010) Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One 5(12): e15194.
37. Nagaraj NS, Datta PK (2010) Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 19(1): 77-91.
38. Pass HI (1993) Photodynamic therapy in oncology: Mechanisms and clinical use. J Natl Cancer Inst 85(6): 443-456.
39. Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI (2013) Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 62(1): 171-182.
40. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5): 775-787.
41. Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25?CD4? T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163(10): 5211-5218.
42. Sieber MW, Claus RA, Witte OW, Frahm C (2011) Attenuated inflammatory response in aged mice brains following stroke. PLoS One 6(10): e26288.
43. Tanaka H, Tanaka J, Kjaergaard J, Shu S (2002) Depletion of CD4? CD25? regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25(3): 207-217.
44. Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4?CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66(8): 4488-4495.
45. Wahl SM, McCartney-Francis N, Allen JB, Dougherty EB, Dougherty SF (1990) Macrophage production of TGF-beta and regulation by TGF-beta. Ann NY Acad Sci 593: 188-196.
46. Wan YY, Flavell RA (2008) TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 28(6): 647-659.
47. Weitzmann MN, Cenci S, Haug J, Brown C, DiPersio J, Pacifici R (2000) B lymphocytes inhibit human osteoclastogenesis by secretion of TGFbeta. J Cell Biochem 78(2): 318-324.
48. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH (2001) Regulatory CD4(?)CD25(?) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12): 4766-4772.